866-997-4948(US-Canada Toll Free)

Xalkori (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jun 2013

Category :

Cancer

No. of Pages : 58 Pages


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Pfizers twice-daily oral tablet, Xalkori, is indicated in the US for the treatment of ALK-positive NSCLC patients, as determined by an FDA-approved companion diagnostic. Xalkori has received conditional marketing authorization in the EU for use in ALK-positive patients, and determination of ALK status is required by any appropriate means.

Scope

  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xalkori including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xalkori for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Xalkori performance
  • Obtain sales forecast for Xalkori from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology and Histology 12
3.1.3 NSCLC Biomarkers 13
3.1.4 Quality of Life 14
3.2 Symptoms 15

4 Disease Management 17
4.1 Treatment Overview 17
4.1.1 Diagnosis 19
4.1.2 Clinical Staging 19
4.1.3 Screening and Early Detection 22
4.1.4 Localized Procedures and Therapies 23
4.1.5 Systemic Chemotherapy 24
4.1.6 Targeted Therapy 25

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Xalkori (crizotinib) 32
6.1 Overview 32
6.2 Efficacy 34
6.3 Safety 36
6.4 SWOT Analysis 37
6.5 Forecast 37

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 44
7.3 Methodology 47
7.4 Forecasting Methodology 47
7.4.1 Number of NSCLC Patients Currently Seeking Treatment 47
7.4.2 Percent Drug-treated Patients 48
7.4.3 General Pricing Assumptions 48
7.4.4 Individual Drug Assumptions 51
7.4.5 Generic Erosion 52
7.5 Physicians and Specialists Included in This Study 52
7.6 Survey of Prescribing Physicians 54
7.7 About the Authors 55
7.7.1 Author 55
7.7.2 Epidemiologist 55
7.7.3 Global Head of Healthcare 56
7.8 About GlobalData 57
7.9 Disclaimer 57

List of Table


Table 1: Symptoms of Disease NSCLC 16
Table 2: Treatment Guidelines for NSCLC 18
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 31
Table 6: Product Profile Xalkori (crizotinib) 34
Table 7: Xalkori SWOT Analysis, 2013 37
Table 8: Global Sales Forecasts ($m) for Xalkori, 2012-2022 38
Table 9: Five Year Prevalence 48
Table 10: Physicians Surveyed by Country 54

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *